1,041 reports of this reaction
5.1% of all NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE reports
#3 most reported adverse reaction
DIZZINESS is the #3 most commonly reported adverse reaction for NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE, manufactured by Nalpropion Pharmaceuticals LLC. There are 1,041 FDA adverse event reports linking NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE to DIZZINESS. This represents approximately 5.1% of all 20,475 adverse event reports for this drug.
Patients taking NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is moderately reported among NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to dizziness, the following adverse reactions have been reported for NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 1,041 FDA reports for NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 5.1% of all adverse event reports for NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience dizziness while taking NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.